vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Natural Grocers by Vitamin Cottage, Inc. (NGVC). Click either name above to swap in a different company.
Natural Grocers by Vitamin Cottage, Inc. is the larger business by last-quarter revenue ($335.6M vs $281.3M, roughly 1.2× Guardant Health, Inc.). Natural Grocers by Vitamin Cottage, Inc. runs the higher net margin — 3.4% vs -45.7%, a 49.1% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 1.6%). Natural Grocers by Vitamin Cottage, Inc. produced more free cash flow last quarter ($11.6M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 4.4%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Natural Grocers by Vitamin Cottage, Inc. is a U.S.-based specialty retail chain that offers certified organic groceries, dietary supplements, natural personal care items, and eco-friendly household products. It serves health-conscious consumers across multiple U.S. states, following strict quality standards that exclude artificial preservatives, colors, flavors and harmful additives.
GH vs NGVC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $335.6M |
| Net Profit | $-128.5M | $11.3M |
| Gross Margin | 64.6% | 29.5% |
| Operating Margin | -43.0% | 4.4% |
| Net Margin | -45.7% | 3.4% |
| Revenue YoY | 39.4% | 1.6% |
| Net Profit YoY | -15.8% | 14.0% |
| EPS (diluted) | $-1.01 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $335.6M | ||
| Q3 25 | $265.2M | $336.1M | ||
| Q2 25 | $232.1M | $328.7M | ||
| Q1 25 | $203.5M | $335.8M | ||
| Q4 24 | $201.8M | $330.2M | ||
| Q3 24 | $191.5M | $322.7M | ||
| Q2 24 | $177.2M | $309.1M | ||
| Q1 24 | $168.5M | $308.1M |
| Q4 25 | $-128.5M | $11.3M | ||
| Q3 25 | $-92.7M | $11.8M | ||
| Q2 25 | $-99.9M | $11.6M | ||
| Q1 25 | $-95.2M | $13.1M | ||
| Q4 24 | $-111.0M | $9.9M | ||
| Q3 24 | $-107.8M | $9.0M | ||
| Q2 24 | $-102.6M | $9.2M | ||
| Q1 24 | $-115.0M | $8.0M |
| Q4 25 | 64.6% | 29.5% | ||
| Q3 25 | 64.7% | 29.5% | ||
| Q2 25 | 65.0% | 29.9% | ||
| Q1 25 | 63.3% | 30.3% | ||
| Q4 24 | 61.6% | 29.9% | ||
| Q3 24 | 61.1% | 29.6% | ||
| Q2 24 | 59.1% | 29.2% | ||
| Q1 24 | 61.2% | 29.3% |
| Q4 25 | -43.0% | 4.4% | ||
| Q3 25 | -37.3% | 4.6% | ||
| Q2 25 | -45.9% | 4.7% | ||
| Q1 25 | -54.6% | 5.2% | ||
| Q4 24 | -62.4% | 4.0% | ||
| Q3 24 | -61.3% | 3.7% | ||
| Q2 24 | -56.8% | 4.2% | ||
| Q1 24 | -59.2% | 3.7% |
| Q4 25 | -45.7% | 3.4% | ||
| Q3 25 | -35.0% | 3.5% | ||
| Q2 25 | -43.0% | 3.5% | ||
| Q1 25 | -46.8% | 3.9% | ||
| Q4 24 | -55.0% | 3.0% | ||
| Q3 24 | -56.3% | 2.8% | ||
| Q2 24 | -57.9% | 3.0% | ||
| Q1 24 | -68.2% | 2.6% |
| Q4 25 | $-1.01 | $0.49 | ||
| Q3 25 | $-0.74 | $0.51 | ||
| Q2 25 | $-0.80 | $0.50 | ||
| Q1 25 | $-0.77 | $0.56 | ||
| Q4 24 | $-0.90 | $0.43 | ||
| Q3 24 | $-0.88 | $0.38 | ||
| Q2 24 | $-0.84 | $0.40 | ||
| Q1 24 | $-0.94 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $23.2M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $220.0M |
| Total Assets | $2.0B | $668.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $23.2M | ||
| Q3 25 | $580.0M | $17.1M | ||
| Q2 25 | $629.1M | $13.2M | ||
| Q1 25 | $698.6M | $21.2M | ||
| Q4 24 | $525.5M | $6.3M | ||
| Q3 24 | $585.0M | $8.9M | ||
| Q2 24 | $933.7M | $13.9M | ||
| Q1 24 | $1.0B | $11.0M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $220.0M | ||
| Q3 25 | $-354.5M | $212.4M | ||
| Q2 25 | $-305.5M | $202.5M | ||
| Q1 25 | $-250.8M | $193.0M | ||
| Q4 24 | $-139.6M | $181.9M | ||
| Q3 24 | $-60.1M | $174.3M | ||
| Q2 24 | $-1.6M | $167.8M | ||
| Q1 24 | $68.3M | $160.0M |
| Q4 25 | $2.0B | $668.6M | ||
| Q3 25 | $1.3B | $670.5M | ||
| Q2 25 | $1.3B | $659.0M | ||
| Q1 25 | $1.3B | $664.6M | ||
| Q4 24 | $1.5B | $648.9M | ||
| Q3 24 | $1.5B | $655.5M | ||
| Q2 24 | $1.6B | $654.4M | ||
| Q1 24 | $1.7B | $656.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $21.1M |
| Free Cash FlowOCF − Capex | $-54.2M | $11.6M |
| FCF MarginFCF / Revenue | -19.3% | 3.4% |
| Capex IntensityCapex / Revenue | 9.9% | 2.9% |
| Cash ConversionOCF / Net Profit | — | 1.86× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $42.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $21.1M | ||
| Q3 25 | $-35.4M | $15.6M | ||
| Q2 25 | $-60.3M | $2.9M | ||
| Q1 25 | $-62.7M | $34.1M | ||
| Q4 24 | $-64.5M | $2.7M | ||
| Q3 24 | $-51.1M | $24.5M | ||
| Q2 24 | $-94.0M | $12.4M | ||
| Q1 24 | $-30.3M | $20.2M |
| Q4 25 | $-54.2M | $11.6M | ||
| Q3 25 | $-45.8M | $7.5M | ||
| Q2 25 | $-65.9M | $-4.2M | ||
| Q1 25 | $-67.1M | $27.6M | ||
| Q4 24 | $-83.4M | $-6.9M | ||
| Q3 24 | $-55.3M | $18.0M | ||
| Q2 24 | $-99.1M | $3.6M | ||
| Q1 24 | $-37.2M | $9.8M |
| Q4 25 | -19.3% | 3.4% | ||
| Q3 25 | -17.3% | 2.2% | ||
| Q2 25 | -28.4% | -1.3% | ||
| Q1 25 | -33.0% | 8.2% | ||
| Q4 24 | -41.3% | -2.1% | ||
| Q3 24 | -28.9% | 5.6% | ||
| Q2 24 | -55.9% | 1.2% | ||
| Q1 24 | -22.1% | 3.2% |
| Q4 25 | 9.9% | 2.9% | ||
| Q3 25 | 3.9% | 2.4% | ||
| Q2 25 | 2.4% | 2.2% | ||
| Q1 25 | 2.2% | 1.9% | ||
| Q4 24 | 9.4% | 2.9% | ||
| Q3 24 | 2.2% | 2.0% | ||
| Q2 24 | 2.9% | 2.9% | ||
| Q1 24 | 4.1% | 3.4% |
| Q4 25 | — | 1.86× | ||
| Q3 25 | — | 1.32× | ||
| Q2 25 | — | 0.25× | ||
| Q1 25 | — | 2.60× | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | 2.72× | ||
| Q2 24 | — | 1.35× | ||
| Q1 24 | — | 2.54× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
NGVC
| Grocery | $243.8M | 73% |
| Dietary Supplements | $60.7M | 18% |
| Manufactured Product Other | $31.0M | 9% |
